Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158141 · ClinicalTrials.gov registry record · Phase 3
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
A Phase 3 study, sponsored by NRG Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT04158141 is a Phase 3 study that was terminated before completion, run by NRG Oncology. The registered enrollment target is 16 participants.
The verdict
NCT04158141, a Phase 3 study, was terminated before completion, sponsored by NRG Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery and chemotherapy may work better than surgery and chemotherapy alone for the treatment of malignant pleural mesothelioma.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- RADIATION Intensity-Modulated Radiation Therapy
- PROCEDURE Decortication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-01-29 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04158141
The ClinicalTrials.gov registry entry for NCT04158141 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT04158141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04158141 about?
NCT04158141 is a clinical study titled "Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma". This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high en...
What is the current status of trial NCT04158141?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2020-01-29. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT04158141?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Decortication (PROCEDURE).
Who is sponsoring clinical trial NCT04158141?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.